About The Speaker
Kurt Jenkins
Senior Director of Biologics at Xilio Therapeutics, where he leads antibody discovery, in silico biologics, and protein sciences in support of the company's tumor-activated biologics pipeline
Kurt Jenkins
Kurt Jenkins, PhD is Senior Director of Biologics at Xilio Therapeutics, where he leads antibody discovery, in silico biologics, and protein sciences in support of the company’s tumor-activated biologics pipeline. His work focuses on the discovery and design of conditionally activated immunotherapies, including masked T cell engagers, for the treatment of solid tumors.
Update on Masked T Cell engager Formats and Conditional Activation for Immunotherapy
With more than 15 years of experience in tumor-activatable biologics, Kurt has dedicated his career to advancing this emerging class of cancer medicines toward clinical application, contributing to the advancement of 3 immuno-oncology programs through IND-enabling studies and into clinical trials. He holds a PhD in Biological Sciences from the Irell and Manella Graduate School of Biological Sciences at City of Hope.
Xilio will present data on its portfolio of masked biotherapeutics designed to overcome toxicity limitations of systemically active therapies. Xilio has leveraged its clinically-validated masking technology across a variety of therapeutic formats including a bispecific PD-1/masked IL-2 (XTX501) and multiple masked T cell engagers, demonstrating potent anti-tumor activity with a favorable tolerability profile in preclinical models.